Repros to Webcast Investor and Analyst Day on June 6th
June 03, 2013 09:01 ET
|
Repros Therapeutics Inc.
THE WOODLANDS, Texas, June 3, 2013 (GLOBE NEWSWIRE) -- Repros Therapeutics Inc.® (Nasdaq:RPRX) today announced that it will host a live webcast of its Investor and Analyst Day that is being held...
FDA Recommends Running Phase 2b Trial of Proellex(R)-V in the Treatment of Severe Menstrual Bleeding Associated With Uterine Fibroids
May 22, 2013 20:01 ET
|
Repros Therapeutics Inc.
THE WOODLANDS, Texas, May 22, 2013 (GLOBE NEWSWIRE) -- Repros Therapeutics Inc.® (Nasdaq:RPRX) today announced it has met with the FDA regarding the clinical development of Proellex-V, the...
Repros Therapeutics Inc.(R) Reports First Quarter 2013 Financial Results
May 10, 2013 09:25 ET
|
Repros Therapeutics Inc.
THE WOODLANDS, Texas, May 10, 2013 (GLOBE NEWSWIRE) -- Repros Therapeutics Inc.® (Nasdaq:RPRX) today announced financial results for the first quarter ended March 31, 2013.
Liquidity and...
Repros Reports Second Pivotal Androxal(R) Study Fully Enrolled Ahead of Schedule
May 02, 2013 12:59 ET
|
Repros Therapeutics Inc.
THE WOODLANDS, Texas, May 2, 2013 (GLOBE NEWSWIRE) -- Repros Therapeutics Inc.® (Nasdaq:RPRX) today announced it has fully enrolled the 180 subject second pivotal study (ZA-302) for...
Repros' Proellex(R) in Breast Cancer Phase 2 Study in Collaboration With Northwestern University
April 29, 2013 12:00 ET
|
Repros Therapeutics Inc.
THE WOODLANDS, Texas, April 29, 2013 (GLOBE NEWSWIRE) -- Repros Therapeutics Inc.® (Nasdaq:RPRX) announced it is collaborating with Feinberg School of Medicine and the Breast Cancer Program at...
Repros to Present at the Bank of America Merrill Lynch 2013 Health Care Conference
April 29, 2013 11:32 ET
|
Repros Therapeutics Inc.
Company to Webcast Presentation on May 16, 2013
THE WOODLANDS, Texas, April 29, 2013 (GLOBE NEWSWIRE) -- Repros Therapeutics Inc.® (Nasdaq:RPRX) today announced that Joseph S. Podolski,...
Repros Reports Issuance of Two Additional U.S. Androxal(R) Patents
April 10, 2013 12:22 ET
|
Repros Therapeutics Inc.
Both patents cover the significant co-morbidity associated with low T and Type 2 diabetes
US patents 8,372,887 and 8,377,991 will expire in 2028 and 2031, respectively
THE WOODLANDS,...
Repros Reports Both Primary Endpoints Successfully Met in First Pivotal Study of Androxal(R)
March 27, 2013 20:01 ET
|
Repros Therapeutics Inc.
79-83% in normal testosterone (T) range (FDA requirement 75%)
No patient elevated beyond normal range
Androxal's impact on sperm concentration meets FDA non-inferiority threshold compared...
American Urological Association (AUA) Accepts Androxal(R) Versus Topical Gel Comparative Study for Podium Presentation at Annual Meeting
March 25, 2013 10:03 ET
|
Repros Therapeutics Inc.
Abstract Title: Evaluation of Enclomiphene (Androxal®) and Testim® on Testosterone (T), Pituitary Hormones and Sperm Function
Presenters: Dr. John Dean (Past President...
Repros Therapeutics Inc.(R) Reports Fourth Quarter and Year End 2012 Financial Results
March 18, 2013 09:25 ET
|
Repros Therapeutics Inc.
THE WOODLANDS, Texas, March 18, 2013 (GLOBE NEWSWIRE) -- Repros Therapeutics Inc.® (Nasdaq:RPRX) today announced financial results for the quarter and year ended December 31, 2012.
Liquidity...